Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	124.54B
Revenue (ttm)	22.74B
Net Income (ttm)	4.42B
Shares Out	122.53M
EPS (ttm)	35.93
PE Ratio	28.28
Forward PE	21.70
Dividend	22.50 (2.21%)
Ex-Dividend Date	n/a

Volume	59,236
Average Volume	130,513
Open	1,055.40
Previous Close	1,055.40
Day's Range	992.00 - 1,059.50
52-Week Range	968.05 - 1,251.00
Beta	0.20
RSI	45.12
Earnings Date	Apr 24, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2023, Alivus Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.